Palleon Pharmaceuticals announces IND clearance for its lead candidate E-602

Clinical Impact

Jan 20

Written By Frances Benson

https://palleonpharma.com/press-releases/palleon-pharmaceuticals-announces-ind-clearance-er-immunotherapy-levefor-first-in-class-raging-glyco-immgy/unology/

2022

Frances Benson

Turning Point Therapeutics announces FDA clearance of IND application for combination of Elzovantinib and Aumolertinib in EGFR mutant MET-amplified non-small cell lung cancer

BioTheryX appoints Sahm Nasseri as CBO